Now that the top three UK political parties have laid bare their manifestos before next month’s general election, the NHS Confederation has responded with a call for stability for the health service and political honesty over the scale of the challenge.
News
AZ drug staves off lung cancer progression for 13.5 months
AstraZeneca said this morning that its investigational lung cancer drug AZD9291 delayed disease progression by more than a year.
Lilly picks up North American rights to Erbitux
Bristol-Myers Squibb has transferred North American rights to cancer drug Erbitux (cetuximab) to Eli Lilly, as it hones its focus on the immuno-oncology field.
Actelion moves MS pill into PhIII
Actelion has kicked off Phase III development of its once-daily multiple sclerosis pill ponesimod, with patient enrolment in the OPTIMUM trial expected imminently.
AZ, Immunocore to test melanoma immunotherapy combos
AstraZeneca’s MedImmune is expanding its alliance with private UK biotech Immunocore to carry out combination immunotherapy trials in skin cancer.
FDA OKs first generic of Teva’s MS drug Copaxone
Novartis’ Sandoz has received US approval for the first generic form of Teva’s multiple sclerosis blockbuster Copaxone (glatiramer acetate).
FDA OKs first new chronic heart failure drug in a decade
The US Food and Drug Administration has stamped its seal of approval on Amgen’s Corlanor (ivabradine), bringing millions of patients with chronic heart failure the first new treatment option in nearly 10 years.
Priority review for AbbVie’s hep C drug in Japan
AbbVie’s investigational once-daily oral therapy for patients with genotype 1 chronic hepatitis C will get a priority review from Japan’s Ministry of Health, Labour and Welfare.
Sanofi and Innate partner for targeted antibodies
Sanofi has signed a collaboration agreement with Innate Pharma giving it access to the latter’s technology to to create new Antibody Drug Conjugates.
Pfizer calls time early on Ibrance study
Pfizer is stopping early a late-stage study of Ibrance as a second-line treatment for breast cancer because the drug clearly met progression-free survival targets.
US Orphan status for AZ’ mesothelioma drug
US regulators have awarded AstraZeneca’s cancer immunotherapy tremelimumab Orphan Drug Designation for the treatment of malignant mesothelioma.
FDA Committee recommends label update for AZ’ Onglyza
The cardiovascular safety profile of AstraZeneca’s diabetes drug Onglyza is acceptable, but its label should carry information about the potential increased risk of heart failure, US regulatory advisors have concluded.
J&J beats Q1 estimates, but lowers guidance
Johnson & Johnson beat earnings expectations for the first quarter of the year, but was forced to lower its full-year expectations as results continued to take battering from the strong US dollar.
Merck, NewLink Ebola jab enters third trial
Merck & Co and NewLink Genetics have confirmed that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has begun in Sierra Leone.
The internet of living things is just around the corner
Are we heading for a MinION movement in healthcare? Clive Brown, CTO of Oxford Nanopore Technologies, talks to PharmaTimes about the Internet of Living Things.
